245 related articles for article (PubMed ID: 21976245)
1. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
Pidala J
Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. Novel targets in the treatment of chronic graft-versus-host disease.
Im A; Hakim FT; Pavletic SZ
Leukemia; 2017 Mar; 31(3):543-554. PubMed ID: 27899803
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
[TBL] [Abstract][Full Text] [Related]
6. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
7. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
8. The changing face of graft-versus-host disease.
Schaffer JV
Semin Cutan Med Surg; 2006 Dec; 25(4):190-200. PubMed ID: 17174839
[TBL] [Abstract][Full Text] [Related]
9. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for acute graft-versus-host disease.
Khaled Y; Reddy P; Krijanovski O
Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
[TBL] [Abstract][Full Text] [Related]
12. How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation.
Fuji S; Byrne M; Nagler A; Mohty M; Savani BN
Bone Marrow Transplant; 2021 Jun; 56(6):1248-1256. PubMed ID: 33514922
[TBL] [Abstract][Full Text] [Related]
13. The Pathophysiology and Treatment of Graft-
Teshima T; Hill GR
Front Immunol; 2021; 12():715424. PubMed ID: 34489966
[TBL] [Abstract][Full Text] [Related]
14. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
[TBL] [Abstract][Full Text] [Related]
15. The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.
Ali AM; DiPersio JF; Schroeder MA
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1552-1564. PubMed ID: 27158050
[TBL] [Abstract][Full Text] [Related]
16. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
[TBL] [Abstract][Full Text] [Related]
17. GVHD Prophylaxis 2020.
Gooptu M; Antin JH
Front Immunol; 2021; 12():605726. PubMed ID: 33897681
[TBL] [Abstract][Full Text] [Related]
18. Recognizing and managing chronic graft-versus-host disease.
Lee SJ; Flowers ME
Hematology Am Soc Hematol Educ Program; 2008; ():134-41. PubMed ID: 19074071
[TBL] [Abstract][Full Text] [Related]
19. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning.
Flowers ME; Traina F; Storer B; Maris M; Bethge WA; Carpenter P; Appelbaum F; Storb R; Sandmaier BM; Martin PJ
Bone Marrow Transplant; 2005 Feb; 35(3):277-82. PubMed ID: 15558037
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant.
Vogelsang GB; Lee L; Bensen-Kennedy DM
Annu Rev Med; 2003; 54():29-52. PubMed ID: 12359826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
